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Abstract
Background: Various papers have addressed pros and cons of the stepped wedge cluster randomized trial design
(SWD). However, some issues have not or only limitedly been addressed. Our aim was to provide a comprehensive
overview of all merits and limitations of the SWD to assist researchers, reviewers and medical ethics committees
when deciding on the appropriateness of the SWD for a particular study.
Methods: We performed an initial search to identify articles with a methodological focus on the SWD, and
categorized and discussed all reported advantages and disadvantages of the SWD. Additional aspects were
identified during multidisciplinary meetings in which ethicists, biostatisticians, clinical epidemiologists and
health economists participated. All aspects of the SWD were compared to the parallel group cluster randomized design.
We categorized the merits and limitations of the SWD to distinct phases in the design and conduct of such studies,
highlighting that their impact may vary depending on the context of the study or that benefits may be
offset by drawbacks across study phases. Furthermore, a real-life illustration is provided.
Results: New aspects are identified within all disciplines. Examples of newly identified aspects of an SWD are:
the possibility to measure a treatment effect in each cluster to examine the (in)consistency in effects across
clusters, the detrimental effect of lower than expected inclusion rates, deviation from the ordinary informed
consent process and the question whether studies using the SWD are likely to have sufficient social value.
Discussions are provided on e.g. clinical equipoise, social value, health economical decision making, number
of study arms, and interim analyses.
Conclusions: Deciding on the use of the SWD involves aspects and considerations from different disciplines
not all of which have been discussed before. Pros and cons of this design should be balanced in comparison
to other feasible design options as to choose the optimal design for a particular intervention study.
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Background
The cluster randomized trial design (CRT), in which
(existing) groups of individuals are being randomized,
may be considered when randomization of individual
participants is not feasible or desirable [1]. Standard
CRTs typically use a parallel design where clusters are
randomized to either a control or an experimental inter-
vention for the entire study. Alternatively, CRTs may use
a crossover design where at a fixed point in time clusters
which started with the control treatment switch to the
experimental intervention and clusters which started
with the experimental intervention switch to the control
treatment [1, 2]. The stepped wedge design (SWD), also
called phased or staggered implementation and multiple
baseline design [3–5] (though not perceived as exactly
the same as SWD [6, 7]), is a special type of the CRT
crossover design in which clusters cross over in one dir-
ection only [6, 8, 9]. All clusters start with the control
treatment after which, at pre-specified time points, one
or more clusters switch sequentially to the experimental
intervention until eventually all clusters have received
the new intervention (see Fig. 1). Within this design,
clusters are randomized with respect to the time point
at which they cross over (referred to as step), not with
respect to a treatment condition or order of treatments
as in parallel group or usual crossover designs, respect-
ively. Measurements of the endpoints and other vari-
ables of interest are being taken in all clusters during the
entire study period. A differentiation can be made be-
tween the cohort (longitudinal) and cross-sectional
SWD [6, 10, 11]. In a cohort SWD, the same subjects
within the clusters are being followed over time, hence
the crossover between treatments is then not only at the
cluster level but also at the subject level. In the cross-
sectional SWD, new subjects are being included after
each step, which means that the crossover of treatments
is only at the cluster level.
The interest in the application of the SWD in inter-
vention research has sharply increased over the last
couple of years [6, 12]. This design was applied in particu-
lar to study community level public health interventions
that have been proven effective in individual level trials, in
so-called phase IV effectiveness trials [6, 9, 12–14], and
seems useful for the evaluation of complex healthcare inter-
ventions [6, 7, 9, 12, 14–17]. Yet, there is also extensive de-
bate about whether and when the SWD is actually useful
for intervention studies [14, 16–22]. The SWD seems to
have some natural attractiveness, i.e. the stepwise imple-
mentation of the new intervention in each cluster is logis-
tically advantageous [6, 8, 12] and may increase the
willingness of clusters to participate [6, 13, 23]. However,
this may cause overuse of the SWD, especially when aware-
ness of all potential benefits and drawbacks of this design
as compared to feasible alternative designs is fragmented
and incomplete.
Previous papers [6, 12, 13] have provided an overview
of several perceived pros and cons of the SWD. How-
ever, various aspects of the SWD have not yet or only
limitedly been addressed, such as considerations related
to health economic evaluations of interventions and
study ethics. Moreover, discussions of the statistical as-
pects of the SWD have been limited to sample size and
analysis approaches, but do not include interim analyses
for example. Furthermore, some pros and cons of the
SWD mentioned vary depending on specific characteris-
tics of the study at hand.
Hence, we aim to provide a comprehensive, multidis-
ciplinary overview of the viewpoints on the merits and
limitations of the SWD within the CRT setting. We used
a set of several methodological papers on the SWD as
our starting point to discuss the potential impact of the
various features of the SWD in our multidisciplinary
team, and to identify features that have not yet been dis-
cussed. We set off all identified aspects to the standard
Fig. 1 Illustration of the stepped wedge design, where different (groups of) clusters switch from control to intervention at different time points
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parallel group CRT to show which of them are specific
to the SWD CRT. Finally, we illustrated several issues by
an actual study that applied the SWD. Our overview can
assist researchers, reviewers and ethical committees
when deciding on the appropriateness of the SWD CRT
for a specific intervention study.
Methods
Within a project team consisting of ethicists, biostatis-
ticians, clinical epidemiologists and health economists
(all at assistant, associate, or full professor level), we
started off by reading and discussing landmark papers
describing the stepped wedge design methodology, and
systematic reviews describing in which fields and for
which reasons the stepped wedge design has been ap-
plied. We performed cross-reference checks to find
other papers discussing the merits and drawbacks of
this design. Finally, we performed a screen search to
assure that we did not miss any key papers discussing
the stepped wedge methodology. For this purpose we
searched Medline, Embase, Pubmed and Web of Science,
using the following phrases: step* wedge*, step* wedge*
design, and step* wedge* AND research design. The final
search was performed on February 2, 2015 without date
restrictions. Articles with didactic purposes or reporting
best practice guidelines were also included. Articles only
reporting the results of an SWD evaluating a specific
intervention, without a methodological focus, were
excluded.
Based on the resulting set of articles we identified, cat-
egorized and discussed all reported advantages and dis-
advantages of the SWD in the CRT setting. These served
as a starting point for the identification of new, add-
itional benefits, viewpoints, challenges and problems,
during a series of informal multidisciplinary meetings.
All articles were screened by EH, IT, RG, JR and HK,
and decisions on eligibility of articles were made by
these authors as well. All found and mentioned aspects of
the SWD were discussed and set off to the parallel group
CRT to identify which of these aspects are indeed unique
for the SWD and whether each aspect is an advantage (+)
or disadvantage (−) in comparison to the parallel group
CRT. If the consequences of an aspect may be similar for
the two designs or their impact may be context dependent
this was indicated as (~). The results were categorized into
three study phases: 1) the study design and preparation
phase, 2) the study execution phase, and 3) the data ana-
lysis and interpretation phase.
Results and discussion
An overview of all identified SWD characteristics and
their potential impact is provided in Tables 1, 2, 3 and 4.
Table 1 provides key aspects of the SWD. Tables 2, 3
and 4 contain aspects of the SWD in comparison to the
parallel group CRT, where Table 2 contains aspects re-
lated to the study design and preparation phase, Table 3
those related to the study execution phase, and Table 4
those related to the data analysis and interpretation
phase. We will explain certain aspects (indicated with *
in the tables) in more detail below.
Study design and preparation phase (Table 2)
In comparison to the parallel group CRT design, the
SWD raises two ethical challenges. Although clinical
equipoise and social value are ethical requirements for
both designs, the content of these requirements may
substantially differ in the two designs, as we will explain
below.
Clinical equipoise (2a)
It has been argued that there should be “genuine uncer-
tainty in the expert medical community about the pre-
ferred treatment” before a randomized trial is allowed to
be conducted [24]. Ensuring this uncertainty balances
the duties of physicians as caregivers and researchers. If
there is clinical equipoise among two (or more) treat-
ments, physicians who are researchers do not violate
their therapeutic duties by withholding a (possibly super-
ior) treatment from their patients.
The SWD is frequently used in situations where the
intervention under study has “shown to be effective in
more controlled research settings” or may not have
shown to be effective yet but is strongly believed to do
more good than harm [6, 12]. At first sight, clinical equi-
poise seems to be absent in these situations. At the same
time, one may argue that in spite of the lack of equipoise
all participating clusters will receive the seemingly su-
perior experimental intervention at some point during
the study. This assumption can be questioned: one
should note that although all clusters will receive the ex-
perimental intervention, it does not always mean that all
participating subjects will receive the experimental inter-
vention. In a cohort design this is the case, but in a
cross-sectional SWD only half of the participants will re-
ceive the experimental intervention just as in a parallel
group CRT [16]. Thus the SWD cannot always prevent
that some participants are withheld from the seemingly
superior intervention.
Yet it still remains to be proven whether the experi-
mental intervention that is felt superior is actually better.
An intervention might have shown efficacy (i.e. work
under controlled settings), though still really needs to be
evaluated for effectiveness (i.e. does it work in practice).
Moreover, when both the experimental intervention and
the control arm are established effective interventions
participants are in principle not withheld from care as
usual, even when one of these arms is felt to be slightly
superior before the start of the study. At the same time,
de Hoop et al. BMC Medical Research Methodology 2015, 15: Page 3 of 13
http://www.biomedcentral.com/1471-2288/15/1/
when the risks of the arms substantially differ this must
be disclosed to research participants [25].
Social value and health care decision making (2b and 2c)
Social value implies that research should be conducted
with the aim to produce generalizable health knowledge
that will ultimately improve the health of individuals
and/or the public [26]. This is an important ethical re-
quirement for human subjects research since the re-
sources for research are limited, so should be well-spent,
and people should not be put at risk for the benefit of
science and society if there is no social value to be ex-
pected [26]. Although results obtained from a singular
study using an SWD may lead to health benefits, the so-
cial value of SWD studies may be limited compared to
parallel group CRTs, in particular from a health eco-
nomic perspective. Given a limited research budget, per-
forming one study effectively prohibits the execution of
another study. This is known as the opportunity cost of
a study and represents the “cost” incurred by not enjoy-
ing the benefits (i.e. social value) from the best, alterna-
tive research activity with similar resource costs [27].
The benefits of performing a study can be defined as the
additional insight gained into the health effects, costs
and cost-effectiveness of the experimental intervention
compared with the control treatment. However, this
insight is only valuable when it actually improves deci-
sion making on whether to adopt the experimental inter-
vention immediately, to adopt it while also requiring
additional evidence collection, to adopt it only in re-
search settings in order to collect more evidence, or to
reject the experimental intervention [28]. Such policy
decisions are partially based on the balance between the
monetary costs and the resulting health benefits of the
experimental intervention, i.e. cost-effectiveness. There-
fore, the social value of studies is largest when the cost-
effectiveness of an experimental intervention is highly
uncertain, such that additional evidence may largely re-
duce the risk of making wrong policy decisions.
The following two situations illustrate the limited
usefulness of the SWD from a health economic per-
spective. First, if the cost-effectiveness of the experi-
mental intervention is highly uncertain, new and
unfavourable evidence on health outcomes and costs
may lead to the rejection of the experimental interven-
tion. Such a rejection decision might be costly since all
Table 1 Key general characteristics of the stepped wedge design and their implications
Characteristic Implication
Randomization is usually at the cluster level Statistical analyses need to take into account that measurements of subjects
within a cluster may be correlated
Concealment of allocation will not always be possible. Blinding of outcome
assessment is therefore more difficult to achieve
Cross-over element: each cluster will switch from control
to experimental intervention
The cross-over allows for a within-cluster comparison which may increase
statistical power
Sample size calculations as well as analyses become more complex
Two subtypes:
- switch involves the same patients (cohort-type) Cohort-type SWD allow for within-patient comparison, which may further increase
efficiency, but critical evaluation whether carry-over effects may compromise the
results of the study is necessary
- switch involves different patients (cross-sectional type)
Switch from control to experimental intervention is spread
over calendar time
A research team can plan and execute the switch in treatment in a dedicated way
as not all clusters switch at the same point in time
Interim analyses need to take into account that the number of measurements in the
control and intervention groups are very imbalanced at early stages and will only
be comparable at the end of the study
It offers the possibility to assess changes in cost-effectiveness over time when the
uptake of interventions is difficult or slow due to implementation barriers that need
to be overcome
A study with an SWD may need a relatively long time to complete
All clusters will experience the experimental intervention This feature may enhance participation of clusters in the study
The switch in each cluster allows investigation and monitoring of implementation
problems
Fixed design in which all clusters start at the same point
in time and all steps have the same time span
Preparations for data collection need to be finished in each hospital which can easily
delay the start of the study
Lower than anticipated inclusion rates increase the risk for an underpowered study as
solutions like adding more clusters or extending the length of the remaining steps
seriously affect the design and are not recommended
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clusters will have implemented the intervention by the
end of the SWD study. Indeed, all clusters have
invested but now need to disinvest while the invest-
ment costs may be irrecoverable. On the other hand, if
the decision to implement will not be affected by new
findings, collecting additional evidence on health out-
comes and costs within an SWD is inefficient because
this evidence will not influence policy decisions any-
more and therefore will have no social value. Although
this holds irrespective of whether a parallel group CRT
or SWD design is being used, the higher disinvestment
costs makes this situation more likely for SWD studies.
Health economic methods have been developed to esti-
mate the social value of a study [29, 30]. These, so-called,
value-of-information methods quantify the expected im-
provement in health outcomes and expected changes in
health care costs when the adoption decision can also
include evidence from the new study instead of including
existing evidence only [31]. The expected social value of a
new study increases when the additional evidence it col-
lects will benefit more individuals in the future (that is,
when many individuals are eligible for the experimental
intervention) and when the study rapidly delivers evidence
that remains valuable for a long period of time. Con-
versely, when some individuals would already receive the
experimental intervention the social value of a new study
decreases because treatment would change for fewer indi-
viduals. In particular, only those future individuals that
would have received the control treatment might
benefit from a switch to the experimental interven-
tion. In general, these issues might lead to a lower
social value of an SWD study as compared to a paral-
lel group CRT, as the SWD study may take longer to
complete which reduces the number of future
Table 2 Comparing the SWD to the parallel group CRT: aspects of study design and preparation
Aspect Issue Description
Equipoise ~ (2a)* An SWD may be used in a situation where there is a slight preference for the experimental treatment
[6, 12, 13]. At the same time, equipoise remains a necessary requirement for all studies including SWDs.
Unlike literature suggests, SWDs where equipoise is disturbed from the start should not be undertaken
† Social value ~ (2b)* A study with an SWD may benefit fewer individuals after completion since it typically takes longer to
complete. However, this disadvantage may be offset by faster implementation following the SWD
† Implemen-tation decisions - (2c)* If evidence on the cost-effectiveness of a new intervention is lacking, collecting this evidence may be
valuable to support implementation decisions. However, deimplementation following a negative result
has worse consequences for SWDs than for parallel group CRTs
Disease - (2d) An SWD is not the design of choice for a study in a rapidly spreading disease. A pandemic requires an
efficient, short-term design and analysis [53]
Study design ~ (2e) An SWD might be logistically easier because of the phased implementation of the intervention rather than
implementation of the intervention at (often) half of the clusters simultaneously in a parallel group CRT
[5, 6, 8, 9, 11–13, 16, 34, 54]. However, variations of the parallel group CRT have also been mentioned which
give the opportunity of phased implementation [18, 19, 21]
† + (2f) The SWD offers the possibility to assess cost-effectiveness over time when the uptake of the intervention
is difficult or slow. Even though statistical power to assess time trends may be relatively low, compared to
parallel group CRTs the SWD allows a more accurate assessment of the actual long-term costs and effects
after implementation barriers have been overcome
~ (2g) An SWD may take longer to complete [5, 6, 9, 12, 13, 16, 18, 53–55]
† - (2h)* In an SWD it will be difficult to compare more than 2 treatments whereas in a parallel group CRT more
treatment arms can be added rather easily. Implementing more than 2 treatments may also be of
questionable use in an SWD
Sample size ~ (2i)* An SWD may require fewer clusters than a parallel group CRT [5, 9, 12–14, 16, 17, 21, 34–36]
~ (2j)* An SWD may require a larger total number of subjects and/or measurements than a parallel group CRT,
depending on cluster size, intracluster correlation (ICC) and number of measurement periods [5, 34, 36]
† ~ (2k) The effect of incorporating interim analyses on the total sample size for an SWD is not clear yet
Power ~ (2l) An SWD may have more power than a parallel group CRT due to an increase in the amount of data
collected and the possibility of within-cluster comparisons [5, 6, 9, 12, 13, 16–21, 35, 37, 54, 56]
+ (2m) The ICC has only a minimal effect on power within an SWD (at least in the cross-sectional design)
[9, 11, 13, 35, 48]
Participation + (2n) Clusters may be more willing to participate in an SWD as each cluster will switch to the new (promising)
intervention during the study [6, 13, 23]
Timing of outcome - (2o) The time between steps in an SWD should be long enough to detect a treatment effect [5, 9, 12, 13, 18].
Hence, if it takes a relatively long time before a treatment effect can be detected, the SWD may require a
much longer time period to be completed than the parallel group CRT
+: positive, −: negative, ~: similar consequences/context dependent, *: discussed in results section, †: newly identified aspect
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individuals eligible for the experimental intervention.
This reduction could, however, be compensated by a
faster total implementation process in the entire re-
gion of interest (e.g. country or state) following study
completion for SWD studies as compared to parallel
group CRTs. This advantage depends on the number
of clusters included in the SWD or parallel group
CRT and the number of not included clusters in the
region of interest. If the experimental intervention is
accepted for use in clinical practice, the number of
Table 3 Comparing the SWD to the parallel group CRT: aspects of study execution
Aspect Issue Description
Informed consent ~ (3a)* May be difficult to obtain from subjects at the start of the study [13], and both SWDs and parallel group
CRTs need modified informed consent procedures [57]
In cross-sectional SWDs the informed consent is in essence similar to that of a parallel group CRT. In cohort SWDs
participants will have to understand that the moment of receiving the new intervention is being randomized
Study participation - (3b)* An SWD may have increased risk of drop-outs and drop-ins (contamination) [6, 13, 18, 21, 22, 54]
† Inclusion rate - (3c)* An SWD suffers relatively more from low inclusion rates because adding a cluster or extending the steps
during the trial disrupts the symmetry of the design
† Study duration ~ (3d) The possible longer study duration of SWDs might require interim analyses to avoid long exposure of clusters of
participants to suboptimal care when the new intervention would be clearly inferior/superior to usual care. The
statistical analysis aspects of interim analyses in an SWD are, however, still unclear
† Number of
measurements
- (3e) If collecting data on health outcomes or costs is expensive, it may not be feasible to collect health economic
evidence at each time point (step) in a cohort (longitudinal) SWD. This is particularly relevant if the number of
steps (and hence number of measurements per participant), would be large. Even though a similar parallel
group CRT would require more participants it might require fewer measurements in total [5, 34–36], and therefore
could be more feasible
- (3f) Repeated measurements within the SWD may lead to a higher burden on everyone involved in the study.
In the cross-sectional setting, this will not be a problem for individual participants, but may still be for research
personnel [13, 16, 18, 19, 22, 35]
Blinding - (3g) Blinding of participants and care providers is often impossible within SWD, however this also holds for the
parallel group CRT. Hence, blinding of assessors of the outcomes is advised [6, 11–13, 19]
Improving intervention ~ (3h) Within the SWD it is possible to improve the intervention during the study, though it is questionable whether
it is desirable to do so [12, 18, 22, 56]
+: positive, −: negative, ~: similar consequences/context dependent, *: discussed in results section, †: newly identified aspect
Table 4 Comparing the SWD to the parallel group CRT: aspects of data analysis and interpretation
Aspect Issue Description
Effect estimate - (4a) In an SWD, the unidirectional crossover strategy complicates the statistical analysis [6, 9, 11–13, 36]. Any temporal
trends or fluctuations may (partially) invalidate the statistical analyses used by default [36]. If temporal trends or
fluctuations are expected or found, a simple within-cluster analysis can provide a biased estimate of the treatment
effect [9]. Calendar time is a potential confounder and should be adjusted for in the analysis [37]. Since incorporation of
the effect of time requires a modelling approach, assumption-free analysis methods (nonparametric methods) cannot
be used to analyse SWD data
+ (4b)* In an SWD the effect measure of interest (e.g. difference in means or relative risk) can be calculated for each cluster,
and the (in)consistency in effect estimates across clusters can be examined [37]
† + (4c) In an SWD learning and decay effects over can be assessed over time, i.e. due to more experience with the
intervention outcomes may become better over time. However it could also be that the intervention is well adopted
just after implementation but ‘forgotten’ about after some time (e.g. if the intervention consists of new guidelines)
† Interim analyses - (4d)* Interim analyses within an SWD are less efficient due to the unequal numbers of measurements under the different
treatment arms during the study. For parallel group CRTs these numbers are more comparable during the entire
trial period
† Number of
measurements
+ (4e) Collecting evidence on outcomes at several time steps may allow assessment of the (changes in) these outcomes
during a longer follow-up period in those clusters that crossed over early in the study. This might benefit subsequent
statistical and health economic analyses, for example, when extrapolating beyond the trial horizon
† Unrelated studies + (4f) Collecting health economic evidence in an SWD might also provide insight into general barriers and facilitators to
implementation and into changes in cost-effectiveness when moving from a clinical to a routine care setting. In an
SWD more evidence on implementation is collected than in parallel group CRTs, as the process of implementing
the new intervention can be observed during the study, for all clusters, as opposed to parallel group CRTs where
half of the clusters do not get the intervention during the study, and studying changes in implementation over
time is more limited. This additional evidence might be valuable in the design and execution of other studies, for
example, studies on other interventions in the same disease area
+: positive, −: negative, ~: similar consequences/context dependent, *: discussed in results section, †: newly identified aspect
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clusters in which it still needs to be implemented can
be substantially lower after SWD studies than after
parallel group CRTs.
Study design (2h)
In a parallel group CRT more than two treatment arms
can be included rather easily. For example, usual care
can be compared with two experimental interventions
within the same study, as illustrated by de Smet et al.
[32]. Within the SWD however, this is more difficult.
One question that arises is how the clusters will cross
over from control to the experimental interventions
since there are two possibilities to do so. First, the ex-
perimental interventions can be implemented sequen-
tially, that is, clusters cross over from control to one
experimental intervention first and at a later time point
(step) cross over from this intervention to the other ex-
perimental intervention. Secondly, the cross over to one
of the experimental interventions can take place at the
same time, that is at one step some clusters cross over
from control to the first experimental intervention while
other clusters cross over to the other experimental inter-
vention. In case of the first situation a (much) longer
study period may be required than in the latter situation.
In addition to this practical question, it is unclear what
the appropriate methods are to calculate the required
sample size and to analyse the data resulting from such
a three-arm design. Moreover, the question is whether
the SWD is a suitable design given the aim of a three-
armed study. If there is no practical need to implement
the treatments sequentially in clusters over time, other
designs will probably provide results in a shorter period
of time than the SWD and will therefore be preferable.
If, on the other hand, the experimental treatments con-
sist of training of professionals for example, the sequen-
tial implementation within the SWD may be very
attractive upfront. However, in this example the question
is whether the effects of the experimental interventions
do not carry over within a cluster from one period to an-
other (given that the trainings are substantially different
from each other). One exception to this proposed situ-
ation is when one intervention is an add-on to another
intervention. For example, in the Helping Hands study
[33] one intervention targeted the individual profes-
sionals and included education, reminders and feedback.
The other intervention extended this by targeting the
team level as well and focussed on social influence in
groups and leadership. In this example, sequential imple-
mentation could be a reasonable choice and carry-over
effects would not be an issue. However, since all clusters
will be trained for one or both of the experimental
interventions, the SWD will probably be more expen-
sive than other design options. Given these issues, it
seems questionable whether an SWD is useful if more
than two treatment arms are to be included in one
study.
Sample size (2i and 2j)
The SWD is often thought to be more efficient than the
parallel group CRT since it uses both within- and between-
cluster comparisons to estimate a treatment effect [9].
However, in the comparison of designs a difference should
be made whether efficiency is in terms of the number of
clusters, the number of participants or the total number of
measurements required. Furthermore, a difference should
be made between a cohort and a cross-sectional design. At
the moment, only sample size and power formulae are
available for the cross-sectional setting, hence the following
discussion will be limited to this setting. Finally, a clear def-
inition of what the parallel group CRT entails should be
taken into account. If the parallel group CRT includes only
one follow-up measurement of each participant in the ana-
lysis (i.e. one measurement period of m participants per
cluster), then given an equal cluster size m per measure-
ment period for the SWD, the SWD always requires fewer
clusters than the parallel design [34, 35]. However, whether
in this case the SWD is also more efficient in terms of the
number of participants (which equals the number of mea-
surements in a cross-sectional setting) depends on the
cluster size, intracluster correlation coefficient (ICC), and
the number of steps [34, 36]. In general, if the ICC is small,
the parallel group CRT will have more power, whereas the
SWD will have more power in case of a large ICC [37].
If the analysis of a parallel group CRT includes a base-
line measurement as a covariate (resulting in an analysis
of covariance), then the SWD does not necessarily re-
quire fewer clusters in comparison to a parallel group
CRT with three measurement periods (one baseline and
two follow-up) as shown by Rhoda et al. [5]. They
showed that, given a cluster size of 100 participants per
group per measurement period, if the ICC is rather
small (<0.005) and the number of steps is up to three,
the SWD requires more clusters. In case of four steps
and ICC ≥ 0.005 or at least five steps and ICC ≥ 0.0001,
the SWD requires fewer clusters. However, the total
number of measurements (and hence participants in a
cross-sectional setting) is higher for the SWD in most
cases, except for situations where the ICC ≥ 0.05 and the
number of steps is between five and eight. Note that
when the cluster size changes the cut-offs in ICCs and
numbers of steps will change as well since all of these
factors affect the required number of clusters.
Although the numbers might change slightly when the
third measurement would not be taken into account as
in [5], it can still be expected that the SWD will not al-
ways require fewer clusters nor participants depending
on cluster size, ICC and number of steps. Yet, Hemming
et al. [37] showed that irrespective of the value of the
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ICC, an SWD with four or more steps will have more
power than a parallel group CRT that includes a baseline
period (i.e. a two measurement periods design).
Since the SWD requires fewer clusters than the paral-
lel group CRT in many cases as described above, the
SWD is especially advantageous when the number of
available clusters is limited [12, 14, 16, 21, 22, 34]. Yet,
one should be aware that this may come at the cost of a
higher number of required participants/measurements.
Study execution phase (Table 3)
Informed consent (3a)
Thus far only Zhan et al. [13] have identified informed
consent as a key issue in SWDs by noting that the tim-
ing of the informed consent procedure can be difficult.
In their trial, the Research Ethics Committee considered
it unethical to ask patients informed consent at the start
of the study (when care as usual was delivered). Un-
fortunately, it remained unclear what the exact rea-
soning was for this judgement but some possible
reasons can be listed.
In individual randomized trials, informed consent is
given at once for data collection, randomization and
administering the experimental intervention, whereas
in CRTs participants have to give separate informed
consent for these three elements [38]. In particular
the latter two elements may raise ethical issues. In
CRTs, often the randomization of the clusters has
taken place before participants enter the cluster, for
example, a hospital has been randomized to one of
the treatment arms before a patient enters. Besides, it
is usually impossible for participants to move to an-
other cluster and therefore it is then almost virtually
impossible for a patient to opt-out (for instance in an
emergency situation as in the example of the HEART
study described below). This means that participants
in CRTs need to consent that they have already been
randomized rather than going to be randomized to
one of the treatments. These issues are true irrespect-
ive of the design choice (parallel group or SWD).
Yet, the informed consent for randomization in an
SWD differs from the parallel group CRT in the sense
that in a parallel group CRT a cluster is either random-
ized to the control or the experimental intervention
whereas in an SWD all clusters will start providing the
control intervention but will switch to the experimental
intervention at some point during the study. In a cross-
sectional SWD new participants are included after each
step leading to half of the participants being exposed to
the intervention and the other half to the control. Then
the informed consent process is not different from a par-
allel group CRT. However, if the same participants are
being followed over time (a cohort SWD) participants
must understand that they are not randomized to one of
the treatment arms but that the time point at which they
will switch from the control to the experimental treat-
ment is being randomized. So, although participants in
this situation will receive the experimental treatment at
some time during the study, they should understand that
it could be shortly after the start of the study but that it
could also be almost at the end of the study. Disclosure of
this information may increase the risk of contamination.
Study participation (3b)
Although it is likely that clusters are more willing to par-
ticipate in an SWD than in a parallel group CRT (because
they know they will receive the experimental intervention
somewhere during the study) [6, 13, 23], drop out of clus-
ters could be more likely as well. Especially when clusters
are being randomized to later steps (which they should
not know in advance), they might drop out just because of
this delay (clusters may lose interest [21]) or because a
similar kind of intervention as the experimental one be-
comes available during the study. Drop-out of participants
will not be an issue if new participants are being included
after each step (cross-sectional design). However when
the same participants are being followed over time (cohort
design) there will be an increased risk of drop-out similar
to other longitudinal research designs.
On the other hand, drop-ins may also be more likely
in SWDs than in parallel group CRTs [18]. Drop-ins
may occur at the participant level in two ways: a partici-
pant may already receive the experimental treatment
from his caregiver while this caregiver should give the
control treatment by design, or the participant may
move to another cluster that has already switched to the
experimental treatment. The first type of drop-in could
be considered a non-adherent cluster, which could lead
to biased (contaminated) results if such a participant
would be included in the analysis as if he were in the
control intervention. The effects of the second type of
drop-in may have only limited effect on the results since
such a patient then becomes a member of a different
cluster and his outcomes would be considered to belong
to the ‘new’ cluster. Only if this patient would still report
outcomes to his initial cluster as if he received the con-
trol intervention, bias may occur. These types of drop-
ins can occur in parallel group CRTs as well, but are
more likely in SWD studies because they often take
more time to complete. Drop-ins at the cluster level are
less likely, since clusters agreed with the stepwise imple-
mentation within the study upfront.
Inclusion rate (3c)
The effect of lower than expected inclusion rates can be
very detrimental in SWDs, because it will disturb the
balance in the design and will cause a loss of power.
Whereas in parallel group CRTs the inclusion period can
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be extended rather easily, this is not straightforward in
SWDs since it would mean that the time between steps
needs to be prolonged which may result in a much lon-
ger study period than planned beforehand. This may not
be feasible due to financial or other constraints. Further-
more, such a change during the study will result in different
lengths of time and different numbers of measurements be-
tween steps. If, and how, this may affect the results and val-
idity of the study is not clear yet. Moreover, if the inclusion
rate lags behind and it is therefore decided to prolong the
time between steps, the risk of drop-out may increase due
to further delays for clusters not yet receiving the experi-
mental intervention.
Data analysis and interpretation phase (Table 4)
Measure of effect in each cluster (4b)
Because each cluster in an SWD will switch from control
to intervention, it is possible to calculate the effect meas-
ure of interest (e.g. difference in means, relative risk, odds
ratio) in each cluster and examine the consistency in effect
across clusters [37]. Tools applied in meta-analysis can be
used to visualize (forest plot) and quantify the inconsist-
ency (τ2 and I2 as heterogeneity measures). Consistency in
effect across clusters may increase the strength of the
overall finding, whereas inconsistency may complicate the
interpretation of the overall finding [39]. Reasons for in-
consistency may be explored. Even though the design is
often not powered for these analyses, they may still pro-
vide additional insights [37].
Interim analyses (4d)
Cumulative monitoring of a study might be warranted to
detect potential harmful effects or early dramatic benefits
of a new intervention. Several group sequential methods
are available and extensively studied for individual ran-
domized trials, but little is known about the application of
these methods in the CRT setting. It has been shown that
the Pocock and O’Brien-Fleming boundaries can be ap-
plied to parallel group CRTs with a binary outcome in
order to control the type I error rate, given that all clusters
are recruited simultaneously (i.e. start the trial at the same
time) and individuals are recruited from those cluster se-
quentially [40]. However, the aspect of adjustment of the
effect estimates following a group sequential CRT has not
been studied.
Given that the SWD is most often used when the
intervention is thought to do more good than harm
and in implementation research, stopping early for
harmful effects is unlikely. However, beneficial effects
may lead to early stopping and speeding up imple-
mentation in the clusters which were allocated to
switch treatments at later.
The cross-sectional SWD will use the same recruit-
ment pattern as described for the parallel group CRT.
Hence, the results presented above can be expected to
apply to SWDs as well. However, within the SWD un-
equal numbers of measurements are available for each
condition after each step (with exception of the last
period). That is, at the start of an SWD only measure-
ments under the control condition are available. Then
from the first step onwards, the inequality between the
number of control and experimental intervention mea-
surements becomes smaller, until at the end of the study
the number of measurements under each intervention is
similar. The effects of these inequalities on the statistical
analysis and power at interim time points are yet un-
clear, though the unequal numbers of measurements
under each treatment over time will generally result in a
loss of efficiency [5, 41].
Example: the HEART impact study
Several aspects of the SWD will be illustrated by asses-
sing the HEART Impact study [42–44]. This study uses
a cross-sectional SWD and the inclusion of this study
has recently completed. Patients presenting at an emer-
gency department with chest pain pose a challenge to
physicians since chest pain can be the symptom of an
acute coronary syndrome (i.e. acute myocardial infarc-
tion or unstable angina) requiring prompt treatment.
However, in up to 80 % of the patients it is caused by
another, usually non-life-threatening condition. The
HEART score has been specifically developed to stratify
patients with chest pain according to their risk for car-
diac events. Previous studies have shown that this score
can adequately identify patients with low, medium or
high risk for developing cardiac events [43, 44]. A few
hospitals in the Netherlands already apply the HEART
score, though other clinical prediction rules [45–47] are
being used as well. Yet, the majority of hospitals (or
treating physicians) do not use any of the formal predic-
tion rules.
The aim of the HEART Impact study is to quantify
the impact of the active use of the HEART score in
daily practice on clinical decision making, patient out-
comes (incidence of major adverse cardiac events
within 6 weeks and quality of life), use of health care
resources and costs. The hypotheses are that the use
of the HEART score will be safe (comparable incidence of
major adverse cardiac events when using the HEART
score compared to usual care), will improve the manage-
ment of the patients presenting with chest pain (in par-
ticular fewer hospital admissions and additional testing in
low risk patients when using the HEART score), and will
reduce overall healthcare costs in this group of patients.
Table 5 shows which aspects of the SWD are relevant
in this study. Some of these aspects will be explained in
further detail below.
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Implementation decisions (5a and 5b)
Collecting data on health outcomes and costs in the
HEART Impact study will allow assessment of the cost-
effectiveness of the HEART score compared to usual
care in clinical practice. Cost-effectiveness results are
likely to provide crucial input to a subsequent formal de-
cision on whether to implement the HEART score in the
entire Netherlands. Indeed, the HEART-Impact study is
expected to provide definitive evidence on the
(favourable) cost-effectiveness of the HEART score,
meaning that additional studies would have no social
value. In the (unlikely) event that the collected evidence
would contradict the expected safety and cost savings,
de-implementation of this specific intervention in all
participating hospitals is very straightforward and virtu-
ally costless. Consequently, the collected data on cost-
effectiveness is valuable and likely to be used in decision
making on (further) implementation of the HEART
score.
Informed consent procedure (5f)
In general, informed consent procedures in CRTs,
whether parallel cluster or stepped wedge, are ethically
complex (see above). Obtaining informed consent also
raised ethical issues in the HEART Impact study, in par-
ticular because the intervention under evaluation con-
sists of two steps. The first step is to determine the
HEART score based on routinely collected information
Table 5 Key aspects of the stepped wedge design in the HEART study
Aspect Issue Description
Implemen-tation
decisions
(5a)* Based on the results of previous validation studies it is likely that the HEART score will be cost-effective if applied correctly
(including adherence to management recommendations). The SWD has the benefit to demonstrate the value of the
HEART score in real practice and problems in implementation can be observed and documented in each cluster
(5b)* When a formal decision would be made on nation-wide implementation of the HEART score based on cost-effectiveness
estimates from the HEART Impact study, the costs of disinvestment (de-implementation) have to be considered. As the
intervention under investigation is the use of a clinical prediction model disinvestment costs are likely to be very small and
not much larger in the SWD than they would have been in a parallel group CRT design
Equipoise (5c) Earlier validation studies have demonstrated the ability of the HEART score to stratify patients with chest pain
according their risk of having a serious heart condition. However, it is unclear whether actively using the HEART
score in practice will indeed be safe and improve health care in terms of health care resources, patient burden
and costs
Participation (5d) The use of risk scores in chest pain patients is recommended in (Dutch) guidelines. The SWD was attractive for
hospitals as each hospital would experience using the HEART score during the trial
Preparation (5e) Inclusion in the HEART study started almost a year later than planned as all hospitals need to start at same time.
Procedures in 1 hospital were slow, which contributed to the delayed start
Informed consent (5f)* No informed consent from patients was sought to determine HEART score
Informed consent was asked from patients to collect additional data
Timing of consent: during the initial evaluation by the treating physicians at the emergency department
Study design (5g) A mix of hospitals (with respect to size, city and rural, academic and non-academic) participates in the HEART study
leading to differences in population and standard of care between hospitals. The SWD allows for a within-hospital
comparison reducing the impact of these differences
(5h) A mix of hospitals participates in the HEART study leading to noteworthy variation in numbers of included patients
per hospital which has not been taken into account in the sample size calculation
Blinding (5i) The primary outcome is major adverse cardiac events (MACE), which has some subjective elements. There will be
an adjudication committee blinded for intervention period for the main endpoints
Interim analyses (5j) The HEART study has been classified as a low-risk trial. Therefore, no formal interim analyses are planned. A DSMB is
monitoring the trial in particular to give an independent advice to participating hospitals about continuing the use
of the HEART score at the end of the study only
Sample size (5k) Inclusion rates have been much lower than expected. The study team considered adding clusters or time points to
the study, but decided not to do this because it is unclear how to accommodate such changes properly in the final
statistical analysis. Furthermore, there was considerable uncertainty about the assumptions in the initial sample size
calculation
Method of analysis (5l) A Generalized Linear Mixed model (GLMM)-analysis is planned to take into account the hierarchical nature of the data
(5m) No interim economic evaluation has been planned. Negative results in the health economic analysis could, at least
in theory, lead to de-implementation of the HEART score. As this process requires time and money, depending on
the number of hospitals already switched to HEART, performing a preliminary economic evaluation as part of an
interim analysis might have been worthwhile
(5n) The (in)consistency in effect across clusters (hospitals) will be examined in a explorative way, for instance whether the
effect size varies depending on type or size of hospital
*: discussed below
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directly after presentation. The researchers of the HEART
study received a waiver of informed consent from the re-
search ethics committee for calculating the HEART score
since this score is evidence-based, part of the medical pro-
fessional standard, and determining the score does not in-
volve additional, invasive procedures. The second step of
the HEART intervention is the link between the height of
the HEART score and certain management options, for
example the suggested management for patients with a
low HEART score is discharge to home. In practice, there
was a time interval between the first and second step of
the intervention. During this time interval, the purpose of
the study was explained and informed consent for add-
itional data collection and follow-up was obtained. In the-
ory, there were two ways in which patients could opt out:
(a) patients refuse consent for data collection and for
using the HEART score to guide further treatment deci-
sions; (b) patients refuse consent for data collection but
not for using the HEART score to determine further treat-
ments. At first sight, the latter situation seems unproblem-
atic since physicians do not have to consider alternative
strategies to guide further treatment decisions. However,
the information that is present is essentially the same as in
the first situation. Patients who are given the opportunity
to opt out are in a situation where it is almost impossible
to meaningfully opt out, as we set out earlier in the ethics
section since they cannot go to another hospital. More-
over, if they choose to opt out and hence to receive care as
usual, this care as usual will be based on the clinician’s
professional judgment, which could be guided by the
HEART score, by an alternative risk score that the phys-
ician used to apply previously, or by his or her overall risk
assessment without formal prediction rules.
Conclusions
Our aim was to provide a comprehensive overview of
the pros and cons of the SWD from a multidisciplinary
viewpoint, moving beyond a systematic review only re-
iterating previously discussed aspects. We showed that
many aspects from different disciplines need to be con-
sidered when deciding on a SWD, not all of which have
been discussed before. If researchers consider using an
SWD for their intervention study all these aspects
should be taken into account since seemingly attractive
aspects may be outweighed by negative or yet unclear ef-
fects of other aspects.
Whether the SWD is the best design option for a spe-
cific intervention study needs to be decided by considering
all, multidisciplinary (statistical, methodological, ethical
and health economical) aspects in comparison to other
feasible designs. We agree with Hemming et al. [37] that
the SWD is likely to be preferable for studies where some
evidence of effectiveness of the experimental intervention
is already available, or in cases where the intervention is a
service delivery or policy change that does not need
individual informed consent to be implemented and
where the outcome is preferably available from rou-
tinely collected data. However, the SWD may not be
a good choice in case of a high risk intervention for
which effectiveness has not been shown yet, or in
case of an intervention unlikely or unfeasible to be
de-implemented when proven ineffective.
Several variations on both the simple SWD and paral-
lel group CRT are possible, such as the staggered parallel
group CRT and incomplete SWDs [18, 48]. Although we
did not take these variations into consideration expli-
citly, many of the addressed aspects will still be an issue,
though possibly to a different extent.
We distinguished between cross-sectional and cohort
designs throughout this paper. For many aspects one
can easily see the potential differences. However, for
power and sample size calculations this is not straight-
forward. The available approaches all rely on the cross-
sectional design [5, 9, 35, 48, 49]. If a cohort or a
mixture of the cross-sectional and cohort design is to be
used, both sample size calculations and analyses need to
take into account the correlation over time not only at
the cluster but also at the individual level. Furthermore,
changes over time at both levels should be taken into ac-
count. However, it is not clear yet how to incorporate
these factors into the design and analysis of SWD stud-
ies. Although cohort designs are more efficient than
cross-sectional designs in general [50–52], future re-
search is required to see whether this also holds for the
SWD (given variations in ICC, number of clusters, clus-
ter size and number of steps) before further comparisons
can be made with other designs in this respect.
Several other aspects have been noted to require
further research. For example, methods for sample
size and power calculations so far have been limited
to cross-sectional designs and assumed equal cluster
sizes between both clusters and steps. Besides, the
possibility of including more than two treatment arms
is questionable. Finally, little is known about the use
of interim analyses in CRTs altogether [40]. Given
that one might expect to be able to stop early for ef-
fectiveness within an SWD in situations where there
is already an indication of superiority of the new
intervention, it is important to know how to perform
the interim analyses properly.
In summary, we have provided an overview of all as-
pects of the SWD that should be taken into consider-
ation when a choice will be made between this design
and other valid design options. The SWD is a relatively
new design and therefore further research is warranted
in order to inform researchers, reviewers and ethical
committees better with respect to the question which
design to prefer for the study question at hand.
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